Tevogen Bio Inc. and Semper Paratus Acquisition Corporation Announce Effectiveness of Registration Statement for Business Combination

New York, NY, Jan. 05, 2024 (GLOBE NEWSWIRE) — Tevogen Bio Inc (“Tevogen Bio”), an advanced-stage specialty immunotherapy biotech pioneer and Semper Paratus Acquisition Corporation (“Semper Paratus”) (Nasdaq:LGST, LGSTW), a publicly-traded special purpose acquisition company, today announced that the Securities and Exchange Commission (“SEC”) has declared effective the registration statement on Form S-4 (the “Registration Statement”) filed by Semper Paratus in connection with Tevogen Bio and Semper Paratus’s previously announced proposed business combination (the “Business Combination” or the “Transaction”).

Read more at globenewswire.com